{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-172997","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.401323+00:00","generated_at":"2026-06-25T02:26:59.510629+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Lyell Immunopharma annual meeting elects Class I directors, ratifies auditor","bullets":["Elected Hans Bishop, Catherine Friedman, Robert Nelsen as Class I directors; each received >147M votes for.","Ratified Ernst & Young LLP as independent auditor for FY2022; 192.2M for, 1,241 against.","Quorum achieved with 192,242,640 shares (77.79%) present at June 8, 2022 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-172997","json":"https://secwatch.observer/filing/0001193125-22-172997.json","markdown":"https://secwatch.observer/filing/0001193125-22-172997.md","text":"https://secwatch.observer/filing/0001193125-22-172997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522172997/0001193125-22-172997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312522172997/d357559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:26:59.510629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}